These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9433462

  • 1. Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.
    Manzke O, Tesch H, Diehl V, Bohlen H.
    J Immunol Methods; 1997 Oct 13; 208(1):65-73. PubMed ID: 9433462
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
    Manzke O, Titzer S, Tesch H, Diehl V, Bohlen H.
    Cancer Immunol Immunother; 1997 Oct 13; 45(3-4):198-202. PubMed ID: 9435873
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antigen binding properties of highly purified bispecific antibodies.
    Allard WJ, Moran CA, Nagel E, Collins G, Largen MT.
    Mol Immunol; 1992 Oct 13; 29(10):1219-27. PubMed ID: 1528192
    [Abstract] [Full Text] [Related]

  • 9. Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma.
    Davico Bonino L, De Monte LB, Spagnoli GC, Vola R, Mariani M, Barone D, Moro AM, Riva P, Nicotra MR, Natali PG.
    Int J Cancer; 1995 May 16; 61(4):509-15. PubMed ID: 7538978
    [Abstract] [Full Text] [Related]

  • 10. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
    Manzke O, Tesch H, Lorenzen J, Diehl V, Bohlen H.
    Int J Cancer; 2001 Feb 15; 91(4):516-22. PubMed ID: 11251975
    [Abstract] [Full Text] [Related]

  • 11. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA.
    Leuk Lymphoma; 1995 Nov 15; 19(5-6):381-93. PubMed ID: 8590837
    [Abstract] [Full Text] [Related]

  • 12. An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants.
    Paul S, Connor J, Nesspor T, Haytko P, Boakye K, Chiu ML, Jiang H.
    Protein Expr Purif; 2016 May 15; 121():133-40. PubMed ID: 26826313
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA, Geerars AJ, Bast EJ, de Gast GC, van de Winkel JG, de Lau WB.
    Ther Immunol; 1994 Oct 15; 1(5):279-87. PubMed ID: 7584502
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma.
    Kriangkum J, Xu B, Gervais C, Paquette D, Jacobs FA, Martin L, Suresh MR.
    Hybridoma; 2000 Feb 15; 19(1):33-41. PubMed ID: 10768839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.